Fig. 2

hsa-miR-12462 acts via downregulation of SLC9A1. a Overview of mRNAs in OE and MOCK U937 cells. b–dCCNE1 (b), TP53 (c), and E2F4 (d) transcript expression in wild-type, MOCK-infected, and overexpressing U937 AML cells is shown (b, OE vs. MOCK P = 0.0001; c, OE vs. MOCK P = 0.0001; d, OE vs. MOCK P = 0.0329). Primers were CCNE1 F: AGC GGT AAG AAG CAG AGC AG, R: TTT GAT GCC ATC CAC AGA AA; TP53 F: CCT CAG CAT CTT ATC CGA GTG G, R: TGG ATG GTG GTA CAG TCA GAG C; and E2F4 F: GAG TGG TCC CAT TGA GGT TC, R: GGC AGA GGT GGA GGT GTA G. e Venn diagram of differentially expressed genes as determined by RNA-sequencing analysis. f Protein-protein interaction network of 15 target genes. g Expression of SLC9A1, ARRB1, and CHRNA6 in U937 MOCK-infected and overexpressing U937 cells is shown (MOCK vs. OE P < 0.0001). h Expression of SLC9A1 transcript in wild-type, MOCK-infected, and overexpressing U937 cells is shown. i Expression of SLC9A1, ARRB1, and CHRNA6 in U937 wild-type, MOCK-infected, and overexpressing cells by western blot. GAPDH is used as a control. jSLC9A1 is a direct target of hsa-miR-12462 confirmed by luciferase activity. Luciferase constructs containing the 3′UTR of SLC9A1 or 3′UTR with point mutations